Wound Care News and Research

RSS

Appeals Court stays judgment in Marine Polymer's patent infringement case against HemCon

HemCon Medical Technologies, Inc., announced today that the U.S. Court of Appeals for the Federal Circuit granted HemCon's motion to stay the injunction and final judgment (including the damages award) obtained against it in a patent infringement case brought by Marine Polymer Technologies, Inc.

20 Nov 2010

Derma Sciences net sales for third quarter 2010 increase 17% to $15,096,134

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and nine months ended September 30, 2010.

12 Nov 2010

SANUWAVE third quarter revenues increase to $278,000

SANUWAVE Health, Inc., an emerging medical technology company focused on regenerative medicine, today reported financial results for the three and nine months ended September 30, 2010 and provided a business update.

12 Nov 2010

Quick-Med Technologies awarded $244,000 QTDP grant to advance antimicrobial technology for wound care

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today it has been awarded by the U.S government under Qualifying Therapeutic Discovery Project (QTDP) to advance the development of the company's NIMBUS® technology for wound dressings and wound drains.

4 Nov 2010

Systagenix introduces world's first rapid point of test in wound care

Innovation doesn't come easy" says Steve Atkinson, Systagenix CEO "and neither do great brands, yet our team have been responsible for many innovations within this field over the last four decades. We are now introducing the world's first rapid point of care test in wound care to help clinicians choose the most appropriate dressings and therapies for their patients and monitor their efficacy over time.

3 Nov 2010

New Ostomy Algorithm receives support of nurses

Quantitative and qualitative results of a study conducted with ostomy care nurses support the content validation of a new standardized algorithm for ostomy care, according to an article published this month in the journal Ostomy Wound Management.

29 Oct 2010

Kinetic Concepts 2010 third quarter total revenue increases 2% to $506.7 million

Kinetic Concepts, Inc. today reported third quarter 2010 total revenue of $506.7 million compared to $504.4 million in the third quarter of 2009 and up 2% from the second quarter of 2010.

26 Oct 2010

New PharmaDeals v4 online resource to support pharmaceutical industry

In the current BioPharma economic climate; with smaller companies desperately needing the right development partners for survival and larger ones needing to support their existing businesses through making the right deals, having the best, most comprehensive, intelligence and insights are absolutely essential for success.

21 Oct 2010

Z-Medica enters agreement with two Swedish medical device distributors for QuikClot products

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced that it has signed exclusive distribution agreements with Vingmed AB and Mediplast AB, two leading Swedish medical device distributors, for distribution of its QuikClot line of hemostatic agents in Sweden, Denmark and Norway for the first time.

From Medica Corporation 21 Oct 2010

PMM launches Amputation Prevention Centers of America

Paradigm Medical Management, Inc, a company dedicated to the development, implementation, and management of hospital outpatient wound care, amputation prevention and hyperbaric medicine centers, introduced Amputation Prevention Centers of America, a specialized division of PMM that addresses severe wounds and prevents unnecessary amputations.

14 Oct 2010

DoD awards $1.5 million grant to study nanoemulsion-based therapies for preventing burn wound infections

Researchers from NanoBio Corporation and the University of Michigan Medical School today announced the receipt of a $1.5 million grant from the Department of Defense (DoD) to study the use of nanoemulsion-based therapies for protection against burn and wound infections.

13 Oct 2010

Cytomedix secures $13 million in registered direct offering under equity purchase agreements

Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announced today that the Company has secured approximately $13 million in current and future funding via a registered direct offering and commitments under two separate equity purchase agreements.

11 Oct 2010

Sverica International to acquire CFWH

The Center for Wound Healing, Inc., a leading manager of comprehensive wound care treatment centers that offer wound care and hyperbaric oxygen therapy, today announced that it has entered into a definitive agreement to be acquired by Sverica International, a leading private equity firm, for approximately $41 million.

7 Oct 2010

Wound Care Innovations adds first pharmacy client to growing list of customers

Wound Management Technologies, Inc. announced today that its subsidiary Wound Care Innovations, LLC has added the company's first pharmacy client to its rapidly growing list of customers. Lewis Hall, Inc. of Fort Worth, TX is an independent pharmacy group that has several locations and 30 years experience in wound care, long term care and specialty compounded products for dermatologic use.

6 Oct 2010

RN expert provides an overview on healthcare quality measurement

Students at Louisiana State University today heard an executive with Baton Rouge-based Amedisys talk about how quality is measured in health care and why it should matter to all Americans. Amedisys is the largest home health care and hospice company in the U.S., providing care to more than 35,000 patients every day.

1 Oct 2010

Cardium expands wound healing and tissue regeneration portfolio

Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.

30 Sep 2010

Quick-Med to present abstracts on antimicrobial technologies at Clinical Symposium

Quick-Med Technologies, Inc.a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today its NIMBUS and Stay Fresh antimicrobial technologies will be highlighted at the 2010 Clinical Symposium on Advances in Skin and Wound Care, to be held in Orlando, Florida from September 30 – October 3, 2010.

29 Sep 2010

Viridis BioPharma receives approval to manufacture, market NIMBUS antimicrobial technology in India

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that its proprietary NIMBUS antimicrobial technology has been approved for manufacture, marketing and sale in India. Viridis BioPharma, an India-based manufacturer and marketer of medical devices, received approval by the Food and Drug Administration of India to manufacture and market gauze wound dressings that incorporate NIMBUS antimicrobial technology.

28 Sep 2010

Bio-Dome wound interface dressings superior than GranuFoam

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new in vitro study results. The Engenex Negative Pressure Wound Therapy (NPWT) system's Bio-Dome wound interface showed superior tensile strength and lower simulated bioadhesion when compared with GranuFoam (polyurethane foam).

27 Sep 2010

Patient follow-up complete in SANUWAVE's dermaPACE Phase III IDE trial for diabetic foot ulcers

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in regenerative medicine, today announced the completion of patient follow-up in the Company's pivotal Phase III, Investigational Device Exemption (IDE) clinical trial with dermaPACE™ for the treatment of diabetic foot ulcers.

22 Sep 2010